低密度脂蛋白在绝经后骨质疏松中的作用研究进展

Research progress in the role of LDL in postmenopausal osteoporosis

随着人口老龄化,骨质疏松发病率逐渐升高,其中绝经后骨质疏松占了非常大的比例,况且骨质疏松不易发现,往往发展成骨折才被察觉,给绝经后妇女的日常生活带来了莫大的困扰。然而其发病机制尚不明确,因此积极探索其发病因素与机制成为亟待解决的问题。近年来随着探索的深入,脂代谢紊乱成为研究绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)发病因素的热点之一。绝经后女性脂代谢异常及骨质疏松的发病率均上升,另外,用于治疗两者的药物也被发现有共同的收益,这为绝经后骨质疏松开辟了新的治疗途径。在众多对脂代谢的研究中,低密度脂蛋白(low density lipoprotein,LDL)被发现和绝经后骨质疏松症具有相关性,低密度脂蛋白的升高可能是绝经后骨质疏松的危险因素。本文对绝经后低密度脂蛋白水平、低密度脂蛋白在骨代谢过程中的作用以及降脂药物对绝经后骨质疏松影响的相关报道加以总结,以期为进一步研究低密度脂蛋白与绝经后骨质疏松的关系奠定基础。

As the population ages,the incidence of osteoporosis gradually increases,of which postmenopausal osteoporosis(PMOP)accounts for a very large proportion.Moreover,osteoporosis is not easy to identify,and it often develops into a fracture before it is detected,and this brings a great deal of trouble to the daily life of postmenopausal women.However,its pathogenesis is still unclear.Therefore,actively exploring its pathogenesis factors and mechanism has become an urgent problem to be solved.With the deepening of exploration in recent years,the disorder of lipid metabolism has become one of the hot spots for studying the pathogenesis of PMOP.The incidence rate of abnormal lipid metabolism and osteoporosis in women has increased after menopause.In addition,drugs used to treat both of them have also been found to have common benefits,which opens up a new therapeutic approach for the treatment of PMOP.In many studies of lipid metabolism,low density lipoprotein(LDL)has been found to be related to PMOP,and the increase in low density lipoprotein may be a risk factor for postmenopausal osteoporosis.This article summarizes the reports of postmenopausal low-density lipoprotein levels,the role of low-density lipoproteins in bone metabolism,and the effects of lipid-lowering drugs on PMOP,in order to lay a foundation for further study on the relationship between LDL and PMOP.